Publications in collaboration with researchers from University of Pennsylvania (42)

2024

  1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  2. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  3. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

2023

  1. Direct oral anticoagulants in pediatric venous thromboembolism: Experience in specialized pediatric hemostasis centers in the United States

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 1

  2. Surgical management of acute appendicitis during the European COVID-19 second wave: safe and effective

    European Journal of Trauma and Emergency Surgery, Vol. 49, Núm. 1, pp. 57-67

  3. Techniques for mesoappendix transection and appendix resection: insights from the ESTES SnapAppy study

    European Journal of Trauma and Emergency Surgery, Vol. 49, Núm. 1, pp. 17-32

2022

  1. Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs

    Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328

  2. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

    Blood, Vol. 140, Núm. 11, pp. 1200-1228

2021

  1. Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit

    Schizophrenia Research, Vol. 227, pp. 10-17

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

2020

  1. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study

    The Lancet Neurology, Vol. 19, Núm. 3, pp. 234-246

  2. Exome sequencing identifies PEX6 mutations in three cases diagnosed with Retinitis Pigmentosa and hearing impairment

    Molecular Vision, Vol. 26, pp. 216-225

  3. Identification of a truncated β1-chimaerin variant that inactivates nuclear Rac1

    Journal of Biological Chemistry, Vol. 295, Núm. 5, pp. 1300-1314

  4. Prognostic gene expression signature for high-grade serous ovarian cancer

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1240-1250

2019

  1. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

    European Journal of Immunology, Vol. 49, Núm. 10, pp. 1457-1973

  2. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma

    Journal of Clinical Oncology

2018

  1. A novel FAS mutation with variable expressivity in a family with unicentric and idiopathic multicentric Castleman disease

    Blood Advances, Vol. 2, Núm. 21, pp. 2959-2963

  2. Current technical approaches to brain energy metabolism

    GLIA, Vol. 66, Núm. 6, pp. 1138-1159

  3. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204